How Small Life Sciences Companies Expand Into New Markets

Imen Jelassi
Sep 17, 2024
5 min read

Updated: 11 hours ago

Scientific capability travels well. Commercial reach does not. A small CRO, CDMO or biotech services company can run the same assay, the same batch or the same study for a sponsor in Boston as for one in Basel, and still have no pipeline outside its home market.

This guide covers what actually has to be in place before a small life sciences company enters a new market, why the United States and the United Kingdom are not one market, and how to test a territory before committing budget to it.

The demand is real, the access is not

Outsourcing demand is not the constraint. The global pharmaceutical CRO and CDMO market was estimated at 254.65 billion dollars in 2025 and is projected to reach 277.16 billion dollars in 2026, growing at a compound annual rate of 8.84 percent to 2035, according to Towards Healthcare.

A growing market does not distribute itself. Sponsors do not go looking for a provider they have never heard of in a country they do not buy from. Market growth is a tailwind, and a tailwind only helps a company that is already moving.

Why international expansion stalls for small providers

Three patterns account for most failed expansions, and none of them are about the quality of the science.

No named buyer in the new market. The company knows the country it wants to sell into but not the job titles that sign, the titles that block, or the events that open a window. Outreach goes to whoever answers.
A single message reused everywhere. The positioning that works at home is translated rather than rebuilt. It references local regulatory context, local competitors and local proof that the new market does not recognize.
No local credibility signal. A sponsor evaluating an unfamiliar provider looks for evidence that someone comparable has already trusted them. Without a reference, a case study or a recognizable partner in that market, the conversation stops at qualification.

What has to be true before you enter a market

Four things, in this order. Skipping any of them turns expansion into an expensive experiment.

1. A market-specific ideal client profile

Not a general description of your customer, a description of your customer in that market. Segment, company size, stage, therapeutic area, and the operational problem you solve for them. If your ideal client profile is identical in two countries, it has not been built for either.

2. Regulatory and procurement literacy

You do not need to be a regulatory consultant, but a first conversation collapses if you cannot situate yourself in the buyer's pathway. Knowing whether the sponsor is preparing an IND, a CTA or a marketing authorization, and knowing how their procurement function qualifies a new vendor, is the difference between a technical conversation and a pitch.

3. A credibility signal that the market recognizes

This can be a client reference, an anonymized case study, a scientific publication, a conference presence, or a partner already established there. It does not have to be large. It has to be verifiable and locally relevant.

4. A named person with continuity

Life sciences decisions take months and involve several stakeholders. A rotating cast of senders, or an agency inbox, breaks the continuity that long cycles depend on. Someone has to own the relationship from first contact to signature.

The US and the UK are not one market

Small life sciences companies routinely treat English-speaking markets as a single territory. They behave differently in ways that change the outreach.

Buyer titles differ. A function called outsourcing management in one market may sit under procurement, vendor management or clinical operations in the other. Targeting by title alone produces the wrong list.
Procurement is more formalized in parts of the UK market. Framework agreements and preferred supplier lists mean the first question is often whether you can be bought at all, not whether you are the best fit.
The competitive set is different. A provider that dominates the US mid-market may be unknown in the UK, which changes how you position against alternatives.
Spelling and vocabulary are read as signals. Optimization and optimisation, program and programme. It is a small thing that tells a reader whether the message was written for them or forwarded to them.

The practical rule: build one segment, one message and one target list per market. Two markets means two of each, not one translated twice.

Sequence one market at a time

Entering two markets simultaneously halves the attention each receives and doubles the number of variables when something does not work. A shallow presence in three countries produces less pipeline than a properly worked presence in one.

Pick the market where you already have the strongest credibility signal, even if it is not the largest. The first reference in a market is the hardest to get and the most valuable once you have it.

How to test a market in ninety days

Before committing to a local hire, an office or a conference program, run a bounded test. It costs a fraction of a full entry and answers the questions that matter.

Build a target list of 100 to 150 accounts that match the market-specific ideal client profile, with named contacts rather than generic inboxes.
Write positioning for that market, including the problem statement in the vocabulary buyers there use.
Run consistent outbound for a full quarter, not a burst. In a market with long cycles, a three-week campaign measures nothing.
Track reply rate, qualification rate and the reasons accounts disqualify. The disqualification reasons are usually more informative than the replies.
Attend or target one event where your buyers actually gather, and treat the follow-up as the deliverable rather than the meetings.

At the end of ninety days you will know whether the segment recognizes the problem you solve, whether your message survives contact with local buyers, and whether the pipeline math justifies further investment.

What good looks like at six and twelve months

At six months: a working target list, a message that generates replies at a defensible rate, two or three qualified conversations in progress, and a clear view of who buys and who blocks.

At twelve months: a first signed client or a documented pilot, one usable local reference, a repeatable outreach process, and enough conversion data to forecast rather than hope.

Revenue in year one is a bonus. The asset is a process that produces qualified conversations on demand in a market where you previously had none.

Frequently asked questions

How do small life sciences companies expand into new markets?

By building a market-specific ideal client profile, positioning written for that market, a locally recognized credibility signal, and one named person who owns relationships through long decision cycles.

Should a small CRO or CDMO enter the US and UK markets at the same time?

Usually not. Sequencing one market properly produces more pipeline than a shallow presence in both, because each market needs its own segment definition, message and target list.

How long does it take to build pipeline in a new life sciences market?

Expect six months to reach qualified conversations and around twelve months to a first signed client or documented pilot, because life sciences decisions commonly take six to eighteen months.

What is the difference between the US and UK life sciences markets for business development?

Buyer titles sit in different functions, parts of the UK market use more formalized procurement and preferred supplier lists, the competitive set differs, and spelling conventions signal whether a message was written for that market.

Expand without hiring a local sales team

Corstrate is a PharmD-led business development consultancy that helps small and mid-sized life sciences service providers build pipeline in the US and UK markets. If you are planning an entry into a new market, get in touch or see how fractional business development works.